Advitech

Advitech researches, develops, and commercializes nutraceutical ingredients and products to prevent immune-mediated inflammatory disorders.

Advitech Inc., a health sciences and technology company, engages in the research, development, and commercialization of nutraceutical ingredients and products to prevent immune-mediated inflammatory disorders, such as psoriasis, eczema, and inflammatory bowel disease. The company offers Dermylex for the treatment of mild-to-moderate psoriasis; products for skin regeneration, remodeling, and skin immune support applications; and a line of bioactive growth factors for applications for the immune system and athletic performance. It also has a wound healing research program to develop applications for its XP-828L and IM technological platforms. Advitech provides its products through distributors in Canada, the United States, Mexico, Europe, France, Belgium, Taiwan, and Indonesia. The company was incorporated in 1995 and is headquartered in QuÃbec City, Canada.